JP4614660B2 - 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物 - Google Patents

細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物 Download PDF

Info

Publication number
JP4614660B2
JP4614660B2 JP2003546874A JP2003546874A JP4614660B2 JP 4614660 B2 JP4614660 B2 JP 4614660B2 JP 2003546874 A JP2003546874 A JP 2003546874A JP 2003546874 A JP2003546874 A JP 2003546874A JP 4614660 B2 JP4614660 B2 JP 4614660B2
Authority
JP
Japan
Prior art keywords
cancer
composition
riboflavin
amino acids
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003546874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518361A5 (enExample
JP2005518361A (ja
Inventor
ブルジンスキー，スタニスロー・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005518361A publication Critical patent/JP2005518361A/ja
Publication of JP2005518361A5 publication Critical patent/JP2005518361A5/ja
Application granted granted Critical
Publication of JP4614660B2 publication Critical patent/JP4614660B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003546874A 2001-11-27 2002-11-21 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物 Expired - Fee Related JP4614660B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/995,010 US20030105104A1 (en) 2001-11-27 2001-11-27 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
PCT/US2002/037354 WO2003045372A1 (en) 2001-11-27 2002-11-21 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy

Publications (3)

Publication Number Publication Date
JP2005518361A JP2005518361A (ja) 2005-06-23
JP2005518361A5 JP2005518361A5 (enExample) 2006-01-05
JP4614660B2 true JP4614660B2 (ja) 2011-01-19

Family

ID=25541300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003546874A Expired - Fee Related JP4614660B2 (ja) 2001-11-27 2002-11-21 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物

Country Status (21)

Country Link
US (2) US20030105104A1 (enExample)
EP (1) EP1450781B1 (enExample)
JP (1) JP4614660B2 (enExample)
KR (1) KR100953483B1 (enExample)
CN (1) CN100358527C (enExample)
AT (1) ATE330595T1 (enExample)
BR (1) BR0214430A (enExample)
CA (1) CA2468133C (enExample)
DE (1) DE60212693T2 (enExample)
EA (1) EA009516B1 (enExample)
HU (1) HU230986B1 (enExample)
IL (2) IL162141A0 (enExample)
MX (1) MXPA04004994A (enExample)
NO (1) NO332858B1 (enExample)
NZ (1) NZ532833A (enExample)
PL (1) PL353656A1 (enExample)
RO (1) RO121173B1 (enExample)
SI (1) SI21542A (enExample)
UA (1) UA78977C2 (enExample)
WO (1) WO2003045372A1 (enExample)
ZA (1) ZA200404115B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553099A4 (en) * 2002-08-02 2006-06-28 Inst Radiation Med Amms Pla RIBOFLAVIN DERIVATIVE AND ITS MANUFACTURE AND USES
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
RU2240788C1 (ru) * 2003-09-09 2004-11-27 Воронежская государственная медицинская академия им. Н.Н. Бурденко Детоксикационное средство
PT2319581E (pt) * 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
WO2008008084A2 (en) * 2005-09-19 2008-01-17 Cdm Optics, Inc. Task-based imaging systems
KR101451438B1 (ko) 2006-03-15 2014-10-15 산토리 홀딩스 가부시키가이샤 리보플라빈과 세사민류를 함유하는 조성물
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
JPWO2008105384A1 (ja) * 2007-02-26 2010-06-03 協和発酵バイオ株式会社 シトルリン含有錠剤
EP3342409A1 (en) 2007-03-15 2018-07-04 Suntory Holdings Limited Anti-fatigue agent
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU2014200578B2 (en) * 2008-09-19 2016-08-11 Société des Produits Nestlé S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
CN103355668A (zh) 2008-09-19 2013-10-23 雀巢产品技术援助有限公司 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持
ES2791524T3 (es) 2009-04-03 2020-11-04 Ocera Therapeutics Inc Fenilacetato de L-ornitina y métodos de elaboración del mismo
EP3517110A1 (en) 2009-06-08 2019-07-31 UCL Business PLC Treatment of inflammation using l-ornithine phenylacetate
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
CA2989896C (en) 2010-07-22 2021-02-09 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
KR102069790B1 (ko) * 2010-09-24 2020-01-23 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
TWI489981B (zh) 2010-12-10 2015-07-01 柏萊迪健康科學有限責任公司 使用茉莉酸治療膀胱功能障礙
EP2676664B1 (en) * 2011-02-17 2017-06-21 EA Pharma Co., Ltd. Potentiator of antitumor activity of chemotherapeutic agent
PL2729008T3 (pl) * 2011-07-07 2017-10-31 Res Cancer Institute Of America Systemy, sposoby i formulacje do leczenia raka
EP2968241B1 (en) 2013-03-11 2018-10-31 University of Florida Research Foundation, Inc. Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
CA2928675C (en) * 2013-11-08 2023-09-05 Legacy Healthcare Ltd Method for the management of cancer and cancer treatment-related comorbidities
JP6598425B2 (ja) * 2014-02-27 2019-10-30 花王株式会社 疲労の評価方法
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CN105495582A (zh) * 2015-12-11 2016-04-20 北京康比特体育科技股份有限公司 一款抗疲劳、促恢复的保健食品氨基酸组合物
EP3621947A4 (en) 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
JPS58126767A (ja) * 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5045468A (en) * 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
ES2063882T5 (es) * 1989-10-02 2001-12-01 Novartis Nutrition Ag Hidrolizados de proteinas.
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
WO1994014458A1 (en) * 1992-12-23 1994-07-07 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
FR2705765B1 (fr) * 1993-04-29 1995-08-18 Eurofours Sa Porte de four.
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
US5547927A (en) * 1993-05-28 1996-08-20 Abbott Laboratories Enteral nutritional product for patients undergoing radiation therapy and/or chemotherapy
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
US5776913A (en) * 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
CA2254772C (en) * 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity
US5817927A (en) * 1997-04-11 1998-10-06 Betzdearborn Inc. Method and apparatus for monitoring water process equipment
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
ES2205646T3 (es) 1999-06-26 2004-05-01 B. Braun Melsungen Ag Solucion acuosa para la nutricion parenteral.
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6377094B1 (en) * 2002-03-25 2002-04-23 Oak Technology, Inc. Arbitrary waveform synthesizer using a free-running ring oscillator

Also Published As

Publication number Publication date
WO2003045372A1 (en) 2003-06-05
ZA200404115B (en) 2005-11-30
KR100953483B1 (ko) 2010-04-16
HU230986B1 (hu) 2019-08-28
SI21542A (sl) 2005-02-28
RO121173B1 (ro) 2007-01-30
IL162141A0 (en) 2005-11-20
PL353656A1 (en) 2003-06-02
CA2468133C (en) 2011-02-22
US7427619B2 (en) 2008-09-23
HUP0402240A2 (hu) 2005-02-28
CN1596109A (zh) 2005-03-16
UA78977C2 (en) 2007-05-10
BR0214430A (pt) 2004-11-03
NO332858B1 (no) 2013-01-21
AU2002352843A1 (en) 2003-06-10
KR20040065565A (ko) 2004-07-22
US20030105104A1 (en) 2003-06-05
EA200400737A1 (ru) 2004-12-30
EA009516B1 (ru) 2008-02-28
NO20042364L (no) 2004-06-07
ATE330595T1 (de) 2006-07-15
EP1450781A1 (en) 2004-09-01
EP1450781B1 (en) 2006-06-21
NZ532833A (en) 2006-12-22
CN100358527C (zh) 2008-01-02
MXPA04004994A (es) 2005-04-08
DE60212693D1 (de) 2006-08-03
CA2468133A1 (en) 2003-06-05
US20050182064A1 (en) 2005-08-18
HUP0402240A3 (en) 2012-09-28
DE60212693T2 (de) 2007-07-05
JP2005518361A (ja) 2005-06-23
IL162141A (en) 2009-05-04

Similar Documents

Publication Publication Date Title
JP4614660B2 (ja) 細胞傷害的化学療法の毒性作用を軽減するために有用な、アミノ酸およびリボフラビンの配合物
CN100441220C (zh) 含有组胺酸及丙胺酸的二肽的用于降低尿酸的组合物
AUSTGEN et al. The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues
EP0679081B1 (en) Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation
TW200410680A (en) Nutritiona compositions
JP6773269B2 (ja) 放射線療法および／または化学療法を受けている腫瘍患者における粘膜炎の治療における使用のためのアミノ酸を備える組成物
JP4419390B2 (ja) 炎症性疾患治療予防剤
US20100234308A1 (en) Wake-up remedy
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
US20240122890A1 (en) Use of exogenous ketone esters to induce weight loss in mammals
AU2002352843B2 (en) Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
JPH06256184A (ja) 癌患者用アミノ酸製剤
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
RU2721605C1 (ru) Фармацевтическая композиция для парентерального капельного введения
Hilgers et al. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
LLLGGGGG LGGGGGGGGGS GGGGGGG LLLLLGLL GGGGL GGG LLLL
Polyzos et al. Double biochemical modulation of 5-fluorouracil by methotrexate and folinic acid for the treatment of advanced colorectal cancer
UJIHIRA Effects of Total Parenteral Nutrition on Tumor Growth, and Plasma and Tumor Free Amino Acids in Tumor-bearing Rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101005

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101019

R150 Certificate of patent or registration of utility model

Ref document number: 4614660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131029

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees